FindTrial
Sign In

Vitamin D supplementation in ckronic kidney disease

Impact of vitamin D supplementation on vascular function and oxidative stress in patients with chronic kidney disease: A Randomized Placebo controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/05/003648
Enrollment
120
Registered
2013-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic kidney disease

Interventions

Intervention1: Vitamin D: 300,000 IU colecalciferol at 0 and 8 weeks Control Intervention1: Placebo: Placebo

Sponsors

Department of Biotechnology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: estimated GFR between 15-45 ml/min/1.73 m2

Exclusion criteria

Exclusion criteria: • Patients with Diabetes mellitus • Active smokers • Patients with Hb • Patients not on ACE inhibitors or ARB therapy • Uncontrolled hypertension (BP >150/90 mmHg) • Patients already on Vitamin D or calcium supplementation • Patients with time-averaged serum calcium >8.5 mg/dl or calcium x phosphate product > 55 • Patients with known malignancies • Patients with autoimmune conditions • Patients with heart failure (ejection fraction 500pg/ml) • Rapidly deteriorating renal function • Recent Acute coronary syndrome (within the last 3 months)

Design outcomes

Primary

MeasureTime frame
change in Brachial artery flow mediated dilatationTimepoint: 0 and 16 weeks—

Secondary

MeasureTime frame
Central arterial stiffnessTimepoint: 0 and 16 weeks;Vitamin D levelsTimepoint: 0 and 16 weeks;vWF, Isoprostane, E-selectin, FGF-23Timepoint: 0 and 16 weeks—

Countries

India

Contacts

Public ContactVivekanand Jha

PGIMER

vjha@pginephro.org2755213

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 7, 2026